摘要
目的 探究瑞舒伐他汀治疗冠心病心绞痛的临床效果。方法 选取我院2018年1月至2020年12月收治的40例冠心病心绞痛患者为研究对象,遵循随机数字表法将其分为参照组和研究组,各20例。参照组给予阿托伐他汀治疗,研究组给予瑞舒伐他汀治疗。比较两组的治疗效果。结果 治疗后,研究组的心绞痛发作频率低于参照组,单次心绞痛发作持续时间短于参照组,用药不良反应总发生率低于参照组(P<0.05)。治疗后,研究组的低密度脂蛋白胆固醇(LDL-C)、总胆固醇(TC)、甘油三酯(TG)水平低于参照组,高密度脂蛋白胆固醇(HDL-C)水平高于参照组(P<0.05)。治疗后,研究组的左心室射血分数(LVEF)、6 min步行试验(6MWT)大于参照组,左心室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)小于参照组(P<0.05)。治疗后,研究组的超氧化物歧化酶(SOD)水平高于参照组,丙二醛(MDA)、心肌肌钙蛋白Ⅰ(cTnⅠ)、肌酸激酶同工酶-MB(CK-MB)水平低于参照组(P<0.05)。结论 瑞舒伐他汀治疗冠心病心绞痛的临床效果显著,可降低心绞痛发作频率及次数,改善患者的血脂、心功能、氧化应激、心肌酶指标。
Objective To explore the clinical effect of rosuvastatin in the treatment of coronary heart disease and angina pectoris.Methods Forty patients with coronary heart disease and angina pectoris treated in our hospital from January 2018to December 2020 were selected as the research objects,and the patients were divided into reference group and study group according to the random number table method,with 20 cases in each group.The reference group was treated with atorvastatin,and the study group was treated with rosuvastatin.The therapeutic effects of the two groups were compared.Results After treatment,the frequency of angina pectoris attack in the study group was lower than that in the reference group,the duration of single angina pectoris attack was shorter than that in the reference group,and the total incidence of adverse drug reactions was lower than that in the reference group(P <0.05).After treatment,the levels of low-density lipoprotein cholesterol(LDL-C),total cholesterol(TC) and triglyceride(TG) in the study group were lower than those in the reference group,and the level of high-density lipoprotein cholesterol(HDL-C) was higher than that in the reference group(P<0.05).After treatment,the left ventricular ejection fraction(LVEF) and 6 min walking test(6MWT) in the study group were larger than those in the reference group,and the left ventricular end-diastolic dimension(LVEDD) and left ventricular end-systolic dimension(LVESD) in the study group were smaller than those in the reference group(P<0.05).After treatment,the level of superoxide dismutase(SOD) in the study group was higher than that in the reference group,and the levels of malondialdehyde(MDA),cardiac troponin Ⅰ(cTnⅠ) and creatine kinase isoenzyme-MB(CK-MB) were lower than those in the reference group(P<0.05).Conclusion Rosuvastatin has a significant clinical effect in the treatment of coronary heart disease and angina pectoris,which can reduce the frequency and time of angina pectoris attack,and improve patients’ blood lipids,cardiac function,oxidative stress,myocardial enzyme indexes.
作者
余尚贤
李伟
YU Shangxian;LI Wei(Ankang Hospital of Traditional Chinese Medicine,Ankang 725000,China)
出处
《临床医学研究与实践》
2022年第24期24-26,共3页
Clinical Research and Practice
关键词
瑞舒伐他汀
阿托伐他汀
冠心病心绞痛
血脂
心功能
rosuvastatin
atorvastatin
coronary heart disease and angina pectoris
blood lipids
cardiac function
作者简介
余尚贤(1968-),男,副主任医师,学士。研究方向:心血管疾病方面;通讯作者:李伟,E-mail:liwei.lantian.420@163.com.
